Ms. Jennifer Che, our President and Managing Director, spoke at the Hong Kong Intellectual Property Department’s IP Training Programme on patent commercialization and technology transfer. Since 2020, the IPD has partnered with the Vocational Training Council’s Institute of Professional Education and Knowledge to arrange various IP training programmes. Other speakers include Mr. Michael Lin – a strategic business consultant & President of IIPCC, Dr. David Ai from the London School of Economics and Political Science, and Dr. Vincent Zhong, an expert in IP licensing and technology transfer who worked at Netac Technology Co., Ltd.

Jennifer’s talk, titled ‘Building a Strategic Patent Portfolio for Commercialization,’ taught professionals how to strategically build patent portfolios with a business mindset. Aside from building IP, Jennifer also focused on topics such as IP licensing, ownership transfers, enforcement, and cross-border issues.

Attendees, including IP owners and executives from startups, SMEs, and large enterprises in the innovation sector, found her talk incredibly insightful and beneficial.

We are very thankful to the IPD and PEAK/VTC for this opportunity to help build a deeper understanding of IP and commercialization in Hong Kong.

我们的过去活动

Recommended Insights

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

2025年4月1日
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]

Major and Exciting Changes to China’s Patent Law [Fourth Amendment to China's Patent Law]

2019年2月20日
Major changes are on the horizon for China’s Patent Law, which will see an overhaul in many areas as early as this year (2019). On January 4, 2019, the National People’s Congress in China published the latest draft of the Fourth Amendment to China’s Patent Law. Several draft amendments have been released for public comment […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

Breaking: China Released New Implementation Measures for the New Patent Linkage System

2021年7月14日
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
Top crossarrow-right